200335-75-7

Basic information

• Product Name: Fmoc-D-Asp(OtBu)-Opfp
• Synonyms: (R)-4-tert-butyl 1-perfluorophenyl 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)succinate;Fmoc-D-aspartic acid beta-tert-butyl ester alpha-pentafluorophenyl ester;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-D-aspartic acid 4-(1,1-dimethylethyl) 1-(pentafluorophenyl) ester;(9H-Fluoren-9-yl)MethOxy]Carbonyl D-Asp(OtBu)-Opfp
• CAS NO: 200335-75-7
• Molecular Formula: C29H24F5NO6
• Molecular Weight: 577.5
• Mol File: 200335-75-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 665.98°C at 760 mmHg
• Flash Point: 356.572°C
• Appearance: /
• Density: 1.373g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: Store at 0°C
• PKA: 9.75±0.46(Predicted)
• CAS DataBase Reference: Fmoc-D-Asp(OtBu)-Opfp(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-D-Asp(OtBu)-Opfp(200335-75-7)
• EPA Substance Registry System: Fmoc-D-Asp(OtBu)-Opfp(200335-75-7)

Safety Data

• Hazardous Substances Data: 200335-75-7(Hazardous Substances Data)

Usage

Uses

Fmoc-D-Asp(OtBu)-Opfp is a protected D-aspartic acid (A790020) derivative, useful for synthetic preparation of peptides.

InChI:InChI=1/C29H24F5NO6/c1-29(2,3)41-20(36)12-19(27(37)40-26-24(33)22(31)21(30)23(32)25(26)34)35-28(38)39-13-18-16-10-6-4-8-14(16)15-9-5-7-11-17(15)18/h4-11,18-19H,12-13H2,1-3H3,(H,35,38)/t19-/m1/s1

Upstream product

• 14533-84-7 pentafluorophenyl trifloroacetate 
• 71989-14-5 Fmoc-(tBu)Asp-OH 
• 771-61-9 2,3,4,5,6-pentafluorophenol 
• 71989-14-5 N-(9-fluorenylmethoxycarbonyl)-4-O-tert-butyl-D-aspartic acid 
• 3057-74-7 L-Asp(t-Bu) 
• 88744-04-1 (9-fluorenyl)methyl pentafluorophenyl carbonate 

Downstream Products

• 133565-45-4 (S)-tert-butyl 3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-hydroxybutanoate 
• 920519-32-0 Fmoc-D-Asp(tBu)-D-Thr(Ψ^MeMepro)-OH 
• 155238-94-1 SKF 107647 
• 797751-68-9 N^α-Fmoc-L-Asn-OPfp 
• 1947-37-1 cholecystokinin-4 

Relevant articles and documents

4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium Toluene-4-sulfonate (DMT/NMM/TsO?) Universal Coupling Reagent for Synthesis in Solution

4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium toluene-4-sulfonate (DMT/NMM/TsO?), a representative member of the inexpensive and environmentally-friendly N-triazinylammonium family of sulfonates, has been found to be a very effective coupling reagent for the synthesis of amides, esters and peptides in solution. This study confirms the usefulness of DMT/NMM/TsO? for peptide synthesis in solution, starting from Z-, Fmoc-, and Boc-protected substrates as well as unnatural building blocks. Peptide synthesis with DMT/NMM/TsO? produced high yields, with high crude product purity and low risk of racemization. In all cases, stoichiometric amounts of reagents were used and the standard synthetic procedure, without the need for time-consuming optimization stages or expensive chromatographic purification. DMT/NMM/TsO? was also found to be very useful for the synthesis of oligopeptides using a fragment coupling strategy.

P-toluenosulfonate salt of N-Methyl-N-(3,5-dimathoxy-2,4,6-triazinyl-1-)-morpholine and related compounds for use as condensing reagent in peptide synthesis

The invention refers to new quarternary N-(3,5-disubstituted-1,3,5-triazinyl-1)-ammonium salts of sulfonic acids, with formula 1, where R1 and R2 denote in total or independently a halogen atom, an alkyl group, a substituted alkyl gr

In vitro and in vivo evaluations of THAM derived telomers bearing RGD and Ara-C for tumour neovasculature targeting

As an approach to the development of specific drug delivery systems, a new class of low macromolecular carriers called 'telomers' endowed with an antitumour agent, such as arabinofuranosylcytosine (Ara-C), RGDSK peptidic sequences, as tumour targeting moieties, and tyrosine groups labelled with 125I atoms allowing the in vivo scintigraphic follow up, were synthesized. Their tumour targeting ability was assessed in vivo in mice bearing a murine B16 melanoma. The biological results showed that the presence of RGDSK sequences onto the macromolecules leads to the selective targeting and the accumulation of telomers within the vascularized zone of the tumour. Moreover, such compounds exhibited in vitro a better IC50 (0.015 μM) than pure Ara-C and in vivo an oncostatic index higher than 160%.